Investors & Media | Nutent Therapeutics


VOLT03 by Nutent Therapeutics Delivers Pharmaceutical-grade Curcumin with Enhanced Absorption

BOCA RATON, Fla., July 05, 2018 (GLOBE NEWSWIRE) — The first highly purified and well-regulated pharmaceutical-grade curcumin, the most widely-studied plant-derived medicinal chemical in modern science, is now commercially available. Seeing a need for a purer, more effectively absorbing curcumin, Nutent Therapeutics developed, tested and launched VOLT03.

The active ingredient in the turmeric plant (curcuma longa), curcumin is a natural anti-inflammatory and antioxidant shown to improve brain function. It has also been shown to lower the risk of heart disease, help prevent and possibly aid in cancer treatment, provide relief for patients with arthritis and possibly help in the prevention and treatment of Alzheimer’s disease.

…view full article

Nutent Therapeutics was selected to present at the Nutrition Capital Network’s Investor Meeting

Nutent Therapeutics has been selected to present at the Nutrition Capital Network’s “Technology Investor Meeting IX“ at SupplySide West. Nutent was one of 12 companies to be chosen out of more than 100 applicants. Richard Becker, Nutent’s Chief Executive Officer, will present on September 26, 2017 at 1:30pm. The meeting will be held at the Mandalay Bay Convention Center in Las Vegas, Nevada.

Nutent Therapeutics will commercialize pharmaceutical-grade products that will be differentiated through successful clinical trials across multiple therapeutic areas.

Our Contact

3651 FAU Boulevard Suite 400 Boca Raton FL 33431 United States

Phone : 561-208-3033

Subscribe to the Nutent Therapeutics Newsletter and receive a discount on your first order